May 27, 2019

BSE Limited
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: U.S. FDA classifies the inspection of Lupin's Goa facility as OAI

The Company has received a communication from the U.S. FDA classifying the inspection conducted at its Goa facility between January 28 to February 8, 2019 as Official Action Indicated (OAI). The U.S. FDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

The inspection at the Goa facility had closed with two observations. Based on U.S. FDA's Concept of Operations program, the Company understands that the status of the facility is still under review. The Company does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The Company is in the process of sending further updates of its corrective actions to the U.S. FDA and is hopeful of a positive outcome.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For **LUPIN LIMITED**

APGadre

For **R. V. SATAM**
COMPANY SECRETARY

LUPIN LIMITED MUMBAI INDIA